Australia markets closed

Cynata Therapeutics Limited (CYP.AX)

ASX - ASX Delayed price. Currency in AUD
Add to watchlist
0.5250-0.0150 (-2.78%)
At close: 3:51PM AEST
Full screen
Previous close0.5400
Open0.5400
Bid0.5200 x 1582700
Ask0.5300 x 3535900
Day's range0.5250 - 0.5500
52-week range0.4700 - 1.0868
Volume73,133
Avg. volume146,626
Market cap75.22M
Beta (5Y monthly)0.39
PE ratio (TTM)N/A
EPS (TTM)-0.0590
Earnings date26 Aug 2021 - 27 Aug 2021
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Simply Wall St.

    We're Interested To See How Cynata Therapeutics (ASX:CYP) Uses Its Cash Hoard To Grow

    We can readily understand why investors are attracted to unprofitable companies. For example, although...

  • GlobeNewswire

    Ethics Approval for Cynata’s Clinical Trial in Diabetic Foot Ulcers

    Key highlights Ethics approval received for clinical trial in patients with diabetic foot ulcers First clinical trial to utilise the wound dressing technology recently licensed from TekCyte Patient recruitment expected to commence in 2H CY21 MELBOURNE, Australia, June 30, 2021 (GLOBE NEWSWIRE) -- Cynata Therapeutics Limited (ASX: “CYP”, “Cynata”, or the “Company”), a clinical-stage biotechnology company specialising in cell therapeutics, is pleased to announce that it has received approval by th

  • GlobeNewswire

    Cynata signs Licence Agreement with TekCyte to advance Clinical Trial in Diabetic Foot Ulcers

    MELBOURNE, Australia, June 03, 2021 (GLOBE NEWSWIRE) -- Cynata Therapeutics Limited (ASX: “CYP”, “Cynata”, or the “Company”), a clinical-stage biotechnology company specialising in cell therapeutics, has today announced the execution of a worldwide exclusive licence agreement with TekCyte Pty Ltd (TekCyte) in respect of TekCyte’s wound dressing technology. Cynata has also secured an option to purchase the relevant technology outright. Key highlights Secured worldwide exclusive licence agreement